Last updated: 2026-09-16 14:41:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
MeiraGTx Holdings plc (MGTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $12.86, with a market capitalisation of $1.24B and a P/E ratio of 15.52. Over the past 52 weeks, its price has ranged from $6.62 to $15.35. This page covers its latest market performance, valuation, price trends and company information.
$1.24B | |
$12.79 | |
$30.23 | |
$3.49 | |
$12.76 | |
106.88K | |
849.21K | |
15.52 | |
$15.35 | |
$6.62 | |
-- | |
-- |
MeiraGTx Holdings plc (MGTX) is currently trading at $12.86 as of 2026-09-16 14:39:00, up 0.75% ($0.10) from the previous close of $12.76
During today's regular trading session, MGTX has traded between $3.49 and $30.23, with a trading volume of 106.88K shares. The current price is near the middle of today's range.
Over the past seven days, MeiraGTx Holdings plc (MGTX) moved from $13.89 to $12.86, representing a decline of 7.44% ($1.03).
The stock traded between $12.50 and $14.05 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 624.42 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 71.4%
MGTX is currently trading at $12.86, placing it 71.4% of the way from its 52-week low of $6.62 to its 52-week high of $15.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 393 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MeiraGTx Holdings plc (MGTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.